| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Merlin L Robb | Q56871310 |
| Jerome H Kim | Q56871312 | ||
| Jean-Louis Excler | Q59690019 | ||
| P2860 | cites work | Design and pre-clinical evaluation of a universal HIV-1 vaccine | Q21092234 |
| HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells | Q22251066 | ||
| Preexposure chemoprophylaxis for HIV prevention in men who have sex with men | Q24612082 | ||
| Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women | Q24629582 | ||
| Structural insights on the role of antibodies in HIV-1 vaccine and therapy | Q26829461 | ||
| A Blueprint for HIV Vaccine Discovery | Q26829865 | ||
| HIV-1 neutralizing antibodies: understanding nature's pathways | Q27000480 | ||
| HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design | Q27022055 | ||
| Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus | Q27644501 | ||
| Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies | Q27644515 | ||
| Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding | Q27670829 | ||
| Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2 | Q27675879 | ||
| Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors | Q27677104 | ||
| Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor | Q27684529 | ||
| Global epidemiology of HIV infection in men who have sex with men | Q28271559 | ||
| Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial | Q28292876 | ||
| HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis | Q37413781 | ||
| The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. | Q37428017 | ||
| Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? | Q37519312 | ||
| Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. | Q37548329 | ||
| Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. | Q37625296 | ||
| Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission | Q37708741 | ||
| Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems | Q37867102 | ||
| Germinal center B and follicular helper T cells: siblings, cousins or just good friends? | Q37899118 | ||
| HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem | Q37958563 | ||
| CD8(+) T cells in preventing HIV infection and disease | Q37996285 | ||
| Key harm reduction interventions and their impact on the reduction of risky behavior and HIV incidence among people who inject drugs in low-income and middle-income countries. | Q38014629 | ||
| The mechanism of action of MF59 - an innately attractive adjuvant formulation | Q38017390 | ||
| Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President's Emergency Plan for AIDS Relief | Q38026485 | ||
| HIV epidemic in Asia: optimizing and expanding vaccine development | Q38036687 | ||
| Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. | Q38069264 | ||
| HIV vaccine efficacy and immune correlates of risk | Q38137212 | ||
| Nanoparticle vaccines | Q38167942 | ||
| Adeno-associated virus delivery of broadly neutralizing antibodies | Q38196689 | ||
| Immunologic Basis for Long HCDR3s in Broadly Neutralizing Antibodies Against HIV-1. | Q38219407 | ||
| Lessons from babies: inducing HIV-1 broadly neutralizing antibodies | Q39027406 | ||
| HIV treatment as prevention: how scientific discovery occurred and translated rapidly into policy for the global response | Q39245198 | ||
| Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand | Q39358681 | ||
| Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. | Q39845365 | ||
| Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype | Q41048122 | ||
| Selection of potent immunological adjuvants for vaccine construction | Q41236255 | ||
| Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys | Q41579160 | ||
| Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines | Q41736305 | ||
| Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responses | Q42083780 | ||
| Ending AIDS--is an HIV vaccine necessary? | Q42229681 | ||
| Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines | Q42230293 | ||
| DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge | Q42264022 | ||
| Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys | Q43212235 | ||
| The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors | Q43576040 | ||
| Predictive markers of safety and immunogenicity of adjuvanted vaccines | Q45057515 | ||
| Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay | Q45766845 | ||
| Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. | Q45938142 | ||
| Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study | Q46333832 | ||
| Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate | Q46775963 | ||
| Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference. | Q53172983 | ||
| HIV/AIDS: Allied responses | Q59098581 | ||
| HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine | Q81079566 | ||
| Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand | Q81488462 | ||
| Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction | Q83111898 | ||
| Moving ahead an HIV vaccine: use both arms to beat HIV | Q85075341 | ||
| Neutralizing antibodies to HIV-1 induced by immunization. | Q36603515 | ||
| Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens | Q36638450 | ||
| Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania | Q36697992 | ||
| Designing tomorrow's vaccines | Q36730618 | ||
| Lessons learned from HIV-1 vaccine trials: new priorities and directions | Q36839817 | ||
| Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees | Q36978671 | ||
| Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys | Q37032170 | ||
| Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm | Q37247974 | ||
| Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys | Q37295534 | ||
| T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces | Q37333743 | ||
| Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys | Q37355237 | ||
| Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial | Q28305565 | ||
| Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies | Q28602877 | ||
| Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study | Q28743767 | ||
| Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial | Q28972526 | ||
| Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 | ||
| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
| Broad neutralization coverage of HIV by multiple highly potent antibodies | Q29615361 | ||
| Immune-correlates analysis of an HIV-1 vaccine efficacy trial | Q29617377 | ||
| Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 | ||
| Preexposure prophylaxis for HIV infection among African women | Q29620077 | ||
| Global trends in molecular epidemiology of HIV-1 during 2000-2007. | Q30399382 | ||
| Implications of HIV diversity for the HIV-1 pandemic | Q30422902 | ||
| Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine | Q30578618 | ||
| Behavior change interventions to prevent HIV infection among women living in low and middle income countries: a systematic review | Q30933868 | ||
| HIV-1 group M conserved elements vaccine | Q33308246 | ||
| HIV-1 vaccines: challenges and new perspectives | Q33577972 | ||
| Novel directions in HIV-1 vaccines revealed from clinical trials | Q33645528 | ||
| Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. | Q33693391 | ||
| Development of replication-competent viral vectors for HIV vaccine delivery | Q33694226 | ||
| Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys | Q33712291 | ||
| Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys | Q33712578 | ||
| Early development of broadly neutralizing antibodies in HIV-1-infected infants | Q33764917 | ||
| Which Antibody Functions are Important for an HIV Vaccine? | Q33772637 | ||
| Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease | Q33867353 | ||
| Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. | Q33875160 | ||
| Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination | Q33977866 | ||
| Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities | Q34036470 | ||
| Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines | Q34057711 | ||
| ARV-based HIV prevention for women - where we are in 2014. | Q34180729 | ||
| Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa | Q34225858 | ||
| Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2 | Q34298408 | ||
| The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. | Q34303849 | ||
| Immune clearance of highly pathogenic SIV infection | Q34370314 | ||
| Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial | Q34374835 | ||
| HIV-1 conserved elements p24CE DNA vaccine induces humoral immune responses with broad epitope recognition in macaques | Q34388606 | ||
| Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection | Q34402934 | ||
| Challenges in the design of a T cell vaccine in the context of HIV-1 diversity | Q34423446 | ||
| Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. | Q34434854 | ||
| Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens | Q34438489 | ||
| Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection | Q34444625 | ||
| Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial | Q34562259 | ||
| Accelerating HIV-1 Vaccine Efficacy Trials | Q34580725 | ||
| Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c mice | Q34592940 | ||
| Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies | Q34593647 | ||
| Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo | Q34593860 | ||
| Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody | Q34630446 | ||
| Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins | Q34637968 | ||
| Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial | Q34648825 | ||
| Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials | Q34743329 | ||
| Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses | Q34802680 | ||
| HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. | Q34915786 | ||
| Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals | Q34962766 | ||
| Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine | Q35009558 | ||
| Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L | Q35012462 | ||
| An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study) | Q35057732 | ||
| A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component | Q35076748 | ||
| A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene | Q35110976 | ||
| Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties | Q35540033 | ||
| Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications | Q35619304 | ||
| Antibody-based protection against HIV infection by vectored immunoprophylaxis | Q35658856 | ||
| Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys | Q35729899 | ||
| A critical question for HIV vaccine development: which antibodies to induce? | Q35783015 | ||
| Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 va | Q35826525 | ||
| Nomenclature for immune correlates of protection after vaccination | Q35948780 | ||
| A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge | Q36024470 | ||
| HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. | Q36132728 | ||
| Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study | Q36158727 | ||
| Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family | Q36363231 | ||
| Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo | Q36414891 | ||
| Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. | Q36489415 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | D4-12 | |
| P577 | publication date | 2015-06-19 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Prospects for a globally effective HIV-1 vaccine | |
| P478 | volume | 33 Suppl 4 |
| Q36021144 | Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial |
| Q56936216 | Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model |
| Q37619109 | DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies |
| Q64360270 | HIV Universal Vaccine |
| Q42619001 | HIV prevention & treatment--reasons to rejoice & remain vigilant |
| Q40071705 | Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models |
| Q40285134 | In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses |
| Q38729260 | Liposomal adjuvants for human vaccines |
| Q92400606 | Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual |
| Q37605728 | Multiple T-cell responses are associated with better control of acute HIV-1 infection: An observational study |
| Q36433894 | New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency |
| Q28078726 | Perspectives for immunotherapy: which applications might achieve an HIV functional cure? |
| Q40051921 | Prospecting for an HIV vaccine |
| Q26766628 | Recent update in HIV vaccine development |
| Q41512554 | Retracted: A DNA inducing VLP vaccine designed for HIV and tested in mice |
| Q37175914 | Significant contribution of subtype G to HIV-1 genetic complexity in Nigeria identified by a newly developed subtyping assay specific for subtype G and CRF02_AG. |
| Q43046562 | Strengthening global vaccine access for adolescents and adults |
| Q40393896 | Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers |
Search more.